[Treatment of hypertrophic cardiomyopathy].
The treatment of hypertrophic cardiomyopathy is first and foremost symptomatic, its aim being to counteract dyspnea, angina pectoris, syncopes and lipothymias, palpitations. In therapy, use is made of beta-blockers, propranolol in particular at moderate or high doses, which are often efficacious but readily cause muscular asthenia. Calcium antagonists, especially verapamil, are a therapeutic alternative, often more efficacious but exposing the patient to the risks of iatrogenic effects which are sometimes serious and may even be fatal. Surgical myomectomy is another alternative, the functional results of which are remarkable, more often than not, but the mortality at surgery, although declining progressively, is not negligible and leads to this approach being used only in cases not responding to medical treatment as when infra-aortic septal hypertrophy is accompanied by an "obstruction". The second type of therapeutic approach is the treatment and prevention of rhythmic disorders which are an integral part of the risk of sudden death. Reduction of auricular fibrillation must play a role in the prevention of thrombo-embolic disease. Ventricular arrhythmias, especially sustained attacks of ventricular tachycardia systematically detected by ambulant ECG, ought to be prevented by anti-arrhythmics: beta-blockers, in combination or not with anti-arrhythmics of class I, amiodarone, propafenone, etc.
Bouhour
J B
JB
Lefèvre
M
M
Letard
G
G
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000453:epidemiology; D002312:Cardiomyopathy, Hypertrophic / Q000235:genetics / Q000628:therapy*; D003645:Death, Sudden / Q000453:epidemiology; D004452:Echocardiography; D004562:Electrocardiography; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D014700:Verapamil
Traitement de la myocardiopathie hypertrophique.